Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

[Response judgement - conventional versus new methods].

Diederich S, Engeser P, Junker K, Passlick B, Pfluger T, Pottgen C, Reck M.

Onkologie. 2009;32 Suppl 1:9-17. doi: 10.1159/000215716. Epub 2009 Jun 10. Review. German.

PMID:
19521130
2.

[Molecular diagnostics and imaging].

Fink C, Fisseler-Eckhoff A, Huss R, Nestle U.

Onkologie. 2009;32 Suppl 1:3-8. doi: 10.1159/000215715. Epub 2009 Jun 10. Review. German.

PMID:
19521129
3.

The ANITA trial seals the deal for adjuvant therapy in non-small-cell lung cancer.

Belani CP.

Clin Lung Cancer. 2005 May;6(6):331-2. No abstract available.

PMID:
15943890
4.

[35th Congress of the American Society of Clinical Oncology, Atlanta, USA, 15-18 May 1999. Non-small-cell lung tumors].

Foggi P.

Clin Ter. 1999 May-Jun;150(3):181-6. Italian. No abstract available.

PMID:
10528429
5.

[The effect of haemoglobin levels on prognosis and quality of life of patients with bronchial carcinoma].

Drings P, Wannenmacher M.

Dtsch Med Wochenschr. 2005 Jun 17;130(24):1507-11. German.

PMID:
15942841
6.

Patient selection for neoadjuvant chemotherapy trials.

Narayan K, Quinn MA.

Int J Gynecol Cancer. 2003 Nov-Dec;13(6):912-3. No abstract available.

PMID:
14675335
7.

Re-evaluating duration of therapy in advanced non-small-cell lung cancer: is it really duration or is it more about timing and exposure?

Socinski MA.

J Clin Oncol. 2009 Jul 10;27(20):3268-70. doi: 10.1200/JCO.2009.22.4345. Epub 2009 May 26. No abstract available.

PMID:
19470913
8.

Prognostic impact of [18F]fluorodeoxyglucose positron emission tomography scanning in the era of molecular oncology.

Ryu JS, Hyun IY.

J Clin Oncol. 2014 May 20;32(15):1630. doi: 10.1200/JCO.2013.53.6300. Epub 2014 Apr 21. No abstract available.

PMID:
24752045
9.

Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment.

Bastiaannet E, Wobbes T, Hoekstra OS, van der Jagt EJ, Brouwers AH, Koelemij R, de Klerk JM, Oyen WJ, Meijer S, Hoekstra HJ.

J Clin Oncol. 2009 Oct 1;27(28):4774-80. doi: 10.1200/JCO.2008.20.1822. Epub 2009 Aug 31.

PMID:
19720925
10.

[Lung neoplasms--ultrasonic endoscopy as a first diagnostic tool].

[No authors listed]

Pneumologie. 2008 Apr;62(4):188. doi: 10.1055/s-2008-1074825. German. No abstract available.

PMID:
18393179
11.

Advances in nasopharyngeal carcinoma.

Guigay J.

Curr Opin Oncol. 2008 May;20(3):264-9. doi: 10.1097/CCO.0b013e3282fad846. Review.

PMID:
18391624
12.

AEG I and II: is it one tumor entity?

Lenglinger J, Ringhofer C, Riegler M.

Ann Surg. 2008 Jun;247(6):1080-1; author reply 1081. doi: 10.1097/SLA.0b013e3181758d4b. No abstract available.

PMID:
18520245
13.

[Treatment outcome of locally advanced stage IIIA/B lung cancer].

Cicenas S, Zaliene A, Atkocius V.

Medicina (Kaunas). 2009;45(6):452-9. Lithuanian.

14.

Treatment of locally advanced non-small cell lung cancer.

Fidler MJ, Kim AW, Zusag T, Bonomi P.

Clin Adv Hematol Oncol. 2009 Jul;7(7):455-64, 479-80. Review.

PMID:
19701153
15.

Predicting survival in non-small-cell lung cancer using positron emission tomography: several conclusions from multiple comparisons.

Berman AT, Ellenberg SS, Simone CB 2nd.

J Clin Oncol. 2014 May 20;32(15):1631-2. doi: 10.1200/JCO.2013.54.3074. Epub 2014 Apr 21. No abstract available.

PMID:
24752052
16.

Role of neoadjuvant therapy for esophageal adenocarcinoma.

Ku GY, Ilson DH.

Surg Oncol Clin N Am. 2009 Jul;18(3):533-46. doi: 10.1016/j.soc.2009.03.004. Review.

PMID:
19500742
17.

Prediction model of chemotherapy response in osteosarcoma by 18F-FDG PET and MRI.

Cheon GJ, Kim MS, Lee JA, Lee SY, Cho WH, Song WS, Koh JS, Yoo JY, Oh DH, Shin DS, Jeon DG.

J Nucl Med. 2009 Sep;50(9):1435-40. doi: 10.2967/jnumed.109.063602. Epub 2009 Aug 18.

18.

Early stage lung cancer--new approaches to evaluation and treatment: conference summary statement.

Lynch TJ, Bogart JA, Curran WJ Jr, DeCamp MM, Gandara DR, Goss G, Henschke CI, Jett JR, Johnson BE, Kelly KL, Le Chevalier T, Mulshine JL, Scagliotti GV, Schiller JH, Shaw A, Thatcher N, Vokes EE, Wood DE, Hart C.

Clin Cancer Res. 2005 Jul 1;11(13 Pt 2):4981s-4983s. No abstract available.

19.

[Oligoprogression].

Guckenberger M.

Strahlenther Onkol. 2015 May;191(5):453-5. doi: 10.1007/s00066-015-0826-2. German. No abstract available.

PMID:
26120651
20.

Stage IIIA-N2 NSCLC: a review of its treatment approaches and future developments.

van Meerbeeck JP, Surmont VF.

Lung Cancer. 2009 Sep;65(3):257-67. doi: 10.1016/j.lungcan.2009.02.007. Epub 2009 Mar 13. Review.

PMID:
19285751

Supplemental Content

Support Center